Olema Pharmaceuticals Inc... (OLMA)
Olema Pharmaceuticals Inc. (OLMA) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 930.1M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -204.57M |
| Beta | 2.01 |
| EPS (ttm) | -2.12 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.95 |
| P/B (ttm) | 2.16 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 9, 2026 |
| Ask | n/a |
| Volume | 1,124,504 |
| Avg. Volume (20D) | 1,436,896 |
| Open | 10.44 |
| Previous Close | 10.51 |
| Day's Range | 10.29 - 10.75 |
| 52-Week Range | 5.34 - 36.26 |
| Analyst | Strong Buy |
| Price Target | 40 (276.29%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative ...
Financial Performance
In 2025, Olema Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -162.45M, an increase of 25.47%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for OLMA stock is "Strong Buy". The 12-month stock price forecast is 40, which is upside of 276.29% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
2 months ago · Simply Wall St.
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation GapOlema Pharmaceuticals (NasdaqGS:OLMA) reported preliminary Phase 1 data for oral KAT6 inhibitor OP-3136, showing anti-tumor activity in multiple advanced solid tumors. The early readout highlighted tu...
